Citius Pharmaceuticals, INC 10-Q quarterly reports

Citius Pharmaceuticals reports its first commercial revenue from LYMPHIR, alongside a significant net loss and a 'going concern' warning, necessitating further capital raises.

Citius Pharmaceuticals reports progress on LYMPHIR commercialization and Mino-Lok development, but faces ongoing significant losses and a need for substantial additional capital.

Citius Pharmaceuticals reports a net loss of $11.5 million for the three months ended March 31, 2025, and acknowledges substantial doubt about its ability to continue as a going concern.

Citius Pharmaceuticals reports a net loss for Q1 2025 and expresses concerns about its ability to continue as a going concern without additional funding.

Citius Pharmaceuticals announced its Q3 2024 results, highlighted by the FDA approval of LYMPHIR and the completion of the Citius Oncology spin-off.

Citius Pharmaceuticals reported a net loss of $17.8 million for the six months ended March 31, 2024, and faces uncertainty about its ability to continue as a going concern despite a recent capital raise and the resubmission of its BLA for LYMPHIR.

Citius Pharmaceuticals reported a net loss of $9.2 million for the quarter ended December 31, 2023, and faces uncertainty about its ability to continue as a going concern.